{"page":{"totalFilteredElements":90},"studies":[{"active":true,"description":"Prospektive NIS of trastuzumab Deruxtecan (T-DXd) for adult patients with advanced HER2-positive gastric or Gastroesophageal junction adenocarcinoma who have received a prior Tratsuzumab based regimen , accompanied by a disease registry of patients treated with conventional therapies in a real world setting","eudractNumber":null,"id":10657,"indications":[{"id":"gio","name":"Bösartige Erkrankungen des oberen Verdauungstraktes (Oesophagus, Magen, gastrooesophagealer Übergang)"},{"id":"gio2","name":"Karzinom des gastrooesophagealen Übergangs"},{"id":"gio3","name":"Magenkarzinom"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2024-04-24T09:00:30+02:00","shortTitle":"Prosperity","therapeutical":false,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"}]},{"active":true,"description":"Qualit&#228;tssicherung der Therapie des Ovarialkarzinoms (QS-OVAR)&#160;<div>DRKS00027253<div>DRKS00027253DRKS00027253</div></div>","eudractNumber":null,"id":8573,"indications":[{"id":"gyn","name":"Bösartige Gynäkologische Tumoren (Gebärmutter, Eileiter etc.)"},{"id":"gyn3","name":"Eierstockkrebs (Ovarialkarzinom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2022-06-03T12:47:13+02:00","shortTitle":"QS - OVAR","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Evaluation of Clinical Management and Outcome in High\nRisk or Recurrent Endometrial Cancer - A Real-World \nObservational Study (QS-Endometrium)&#160;","eudractNumber":null,"id":11933,"indications":[{"id":"gyn","name":"Bösartige Gynäkologische Tumoren (Gebärmutter, Eileiter etc.)"},{"id":"gyn1","name":"Gebärmutterkrebs (Uteruskarzinom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2026-01-27T11:56:16+01:00","shortTitle":"QS-Endometrium","therapeutical":false,"therapyLines":[]},{"active":true,"description":"<div>Radical antegrade modular pancreatosplenectomy versus conventional</div><div>distal pancreatosplenectomy for pancreatic cancer &#8211; The multicenter,</div><div>randomized controlled RAMPS-Trial</div>","eudractNumber":null,"id":11072,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu3","name":"Bauchspeicheldrüsenkrebs (Pankreaskarzinom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2025-06-01T13:19:44+02:00","shortTitle":"RAMPS trial","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"Prospective study with continuous and fixed-Duration Ibrutinib based First Line Treatment in patients with Chronic Lymphocytic Leukemnia in real world setting","eudractNumber":null,"id":9253,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2023-03-03T13:01:22+01:00","shortTitle":"Reality 2","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Mammakarzinom des Mannes - Eine prospektive Registerstudie der Universit&#228;tsfrauenklinik Magdeburg in Zusammenarbeit mit der GBG (German Breast Group) zur Diagnostik und Therapie des Mammakarzinoms des Mannes<div><br /></div><div>DRKS00009536</div>","eudractNumber":null,"id":1491,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2009-04-01T14:01:18+02:00","shortTitle":"Registerstudie Mammakarzinom des Mannes","therapeutical":false,"therapyLines":[]},{"active":true,"description":"<div><div><div>Male breast cancer - A prospective registry study of the University Women's Hospital Magdeburg in cooperation with the GBG (German Breast Group) on the diagnosis and treatment of male breast cancer</div><div><br /></div><div>DRKS00009536</div></div><div><br /></div></div>","eudractNumber":null,"id":6191,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2009-09-08T13:56:24+02:00","shortTitle":"Registerstudie Mammakarzinom des Mannes","therapeutical":false,"therapyLines":[]},{"active":true,"description":"PROVIDENCE&#160;- Prospective Non-interventional Study (NIS) to Examine Patient-reported Outcomes and Real-world Clinical Data in Patients With HER2-positive or HER2-low Unresectable or Metastatic Breast Cancer Treated With Trastuzumab Deruxtecan (PROVIDENCE)","eudractNumber":null,"id":10995,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"HER2/neu","id":"mt_19"}],"nctNumber":"NCT05573893","phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2022-09-18T11:55:19+02:00","shortTitle":"Registerstudie PROVIDENCE","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Digital Monitoring with Patient-reported outcomes in cancer care: A randomized controlled trial","eudractNumber":null,"id":11846,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT06867705","phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2026-01-12T11:48:28+01:00","shortTitle":"Resilience- RC-102","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Retentionsrate von Acalabrutinib in einem nicht-interventionellen Setting","eudractNumber":null,"id":9260,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT05645172","phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2023-01-05T09:26:40+01:00","shortTitle":"Retain","therapeutical":false,"therapyLines":[]}]}